Pfizer and BioNTech announce COVID-19 vaccine has met all primary efficacy endpoints in phase III trial and plan to submit Emergency Use Authorisation to FDA
New data from a final efficacy analysis of Pfizer & BioNTech's BNT162b2 vaccine show that it met all of the phase III study’s primary efficacy endpoints, demonstrating that it is 95% effective at preventing COVID-19, consistent across age, gender, race and ethnicity demographics.
Source:
PharmaTimes
SPS commentary:
MHRA Chief Executive said that the results reported by Pfizer today are very encouraging and the Agency is looking forward to receiving the full results of the trials as soon as possible, after which it will rigorously assess the evidence of safety and effectiveness of the vaccine.